Español 
English
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Artículos Relacionados
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. VER MÁS
-
UDIBI
Fecha de publicación: Septiembre 2019 A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced...
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
-
UDIBI
Fecha de publicación: 8 noviembre 22 Altered neutrophil-to-lymphocyte ratio in sepsis secondary to canine parvoviral enteritis treated with and...
-
UDIBI
Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. VER MÁS
-
UDIBI
Fecha de publicación: Marzo 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio Ver más
-
UDIBI
Development and validation of a bioassay to evaluate binding of adalimumab to cell membrane-anchored TNFα using flow cytometry detection....
-
UDIBI
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. VER MÁS
